Forwarded this? Get it weekday mornings: optimized.news/subscribe
Hims & Hers to meet White House on FDA's peptide plan
Take. Peptides stopped being a specialist's niche when Hims asked for a White House meeting on them. If FDA's discretion comes through, the largest public cash-pay telehealth company can sell them nationally, and we think clinics building a peptide menu should price it against Hims.
OIRA's meeting log now lists two meetings on FDA's "Interim Access Policy for Compounding Using Certain Peptides." The American Academy of Peptide Medicine meets reviewers Wednesday at 3 p.m. Hims & Hers Health requested the second, Friday at 2 p.m. It is a notice under review, and its text isn't public. We don't know what Hims will argue.
The odd part is the timing. In March, Hims said it would "no longer advertise compounded GLP-1 offerings" and moved its US weight business toward FDA-approved brands, starting with Novo Nordisk's. Seven months later it wants a say on a compounding policy.
The Alliance for Pharmacy Compounding, the compounders' trade group, is still guessing. CEO Scott Brunner told Semafor the notice is "potentially significant, but we don't yet know what the policy says, which peptides it covers, or what conditions FDA may attach to their compounding." AmSpa told members that enforcement discretion is not approval and that state law still governs.
Correction: Tuesday's issue said OMB has no deadline. The "None" on the review record refers to FDA's deadline. Executive Order 12866 gives OIRA 90 days, plus one 30-day extension.
The Signal
[Medspa] Invoca's new AI agents book the consult and tell Google which ad paid for it
Most clinics can't see which ad produced a booked, kept consult. The booking is recorded in the practice system, and the click is recorded at Google or Meta. Invoca has sold call tracking to connect the two for years. Its healthcare launch puts AI voice and text agents on calls, texts and web forms around the clock. They book, reschedule or cancel inside Epic, athenahealth, ModMed and "leading dental and dermatology practice management systems," PR Newswire carries. De-identified booking results then flow back to Google, Meta, Adobe and The Trade Desk, so the ad systems bid toward patients who show up. Invoca's own benchmark says only 54% of calls to healthcare organizations reach a person. University Hospitals' Matt Eaves says its agent "recovered 25 appointments on its first night." Invoca names hospitals and dental groups as customers. No medspa is on the list yet.
[Telehealth] FDA finalized its guidance on software drug companies release with prescription drugs
It covers sponsor apps and their outputs. Clinic-built apps aren't sponsor software. It publishes Wednesday in the Federal Register.
[Telehealth] Hims launched weight care in Germany, where insurance mostly won't pay
The pitch is the same cash-pay gap US clinics live on. "Statutory health insurance generally doesn't cover weight-loss medications, so the cost often falls on the individual," Hims writes. It starts with men, through private online consults with EU-licensed clinicians. Hims also cites a survey, which it doesn't name, in which 42% of German adults didn't want to discuss their weight with their GP. Growth money is going abroad. Hims reports third-quarter results Nov. 9, and that call should show how much of it.
Wire
Face Forward Aesthetics, an NP-led group with eight locations in Ohio, Pennsylvania and Nevada, added Hugel's Letybo to its injectables menu.
Health Law Alliance walks through FDA's September letter to a Houston pharmacy that called templated "significant difference" notes pretextual. It's a useful read before your next prescriber-form update.
FemWealth counts four women's-health raises totaling about $39 million last week. One is a UK company building an at-home saliva hormone test.
Dates we're watching: the two peptide meetings Wednesday and Friday. OIRA meets on DEA's telemedicine registration rule Nov. 2. The current telemedicine prescribing flexibilities end Dec. 31 unless extended.
Forward this to whoever is pricing your peptide menu. One question, answerable yes or no: would you still add peptides if Hims sold them too?
Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.